Unable to display view head.php file not found.
 
 

James A. Reiffel, MD - Novel Oral Anticoagulants - Figure 47

ARISTOTLE: Primary Outcome

The Figure shows the curves for the percentage of patients with an primary outcome event (stroke or systemic embolism) per time.[99] The result was a hazard ratio of 0.79 with apixaban, p=0.011.  These data are similar to the results with dabigatran in RE-LY,[96] which are shown in a following Figure.

 Reiffel JA. Am J Med 2013; 126: 00-00.

Complete references for all slides

References

[96] Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.

[99] Granger CB, Alexander JH, McMurray JV, et al; the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.

Unable to display view foot.php file not found.